Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Rosen who wrote (6316)	4/9/1999 7:21:00 AM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

You're making a lot of assumptions about the nature of the suit, why it was dismissed, what it means that it was dismissed. You're assuming it means that fraud on the part of the company cannot be proven. I really don't know that your assumptions have basis in fact, so until I see something factual, not based on assumptions, I'll have to withhold judgment. You simply "doubt" that the dismissal was related to stock price. You don't know anything. It may be true that 70% of applications are approved that get this far; I don't question that. I simply think there's a better than 50% chance that Vasomax will be in the 30% group. And you think that it will be in the 70% group. I agree there will be initial sales if approved. But so there were in Mexico, and then NONE. That's what I believe would happen if approved in the US, too: an initial flurry of sales, and then NONE. Because it doesn't work. Linda